Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma

NCT02234115 is registered in ClinicalTrials.gov with Foresee Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT02234115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02234115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2014
Completion date
January 5, 2017
Enrollment
137 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms